Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITAD: Aldesleukin in Type 1 Diabetes
NCT03782636Phase 2Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Jan 2019
- Primary completion
- Feb 2023
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Aldesleukin with Placebo (2 arms). Primary endpoint: Differences in slopes of DBS (Dried Blood Spot) C-peptide at 6 months. Started Jan 2019; status: active, not recruiting.
02
Drugs
aldesleukin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03782636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03782636.